Photodynamic Therapy for Glioblastoma: Illuminating the Path toward Clinical Applicability
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Glioblastoma (GBM) is the most common adult brain cancer. Despite extensive treatment protocols comprised of maximal surgical resection and adjuvant chemo–radiation, all glioblastomas recur and are eventually fatal. Emerging as a novel investigation for GBM treatment, photodynamic therapy (PDT) is a light-based modality that offers spatially and temporally specific delivery of anti-cancer therapy with limited systemic toxicity, making it an attractive option to target GBM cells remaining beyond the margins of surgical resection. Prior PDT approaches in GBM have been predominantly based on 5-aminolevulinic acid (5-ALA), a systemically administered drug that is metabolized only in cancer cells, prompting the release of reactive oxygen species (ROS), inducing tumor cell death via apoptosis. Hence, this review sets out to provide an overview of current PDT strategies, specifically addressing both the potential and shortcomings of 5-ALA as the most implemented photosensitizer. Subsequently, the challenges that impede the clinical translation of PDT are thoroughly analyzed, considering relevant gaps in the current PDT literature, such as variable uptake of 5-ALA by tumor cells, insufficient tissue penetrance of visible light, and poor oxygen recovery in 5-ALA-based PDT. Finally, novel investigations with the potential to improve the clinical applicability of PDT are highlighted, including longitudinal PDT delivery, photoimmunotherapy, nanoparticle-linked photosensitizers, and near-infrared radiation. The review concludes with commentary on clinical trials currently furthering the field of PDT for GBM. Ultimately, through addressing barriers to clinical translation of PDT and proposing solutions, this review provides a path for optimizing PDT as a paradigm-shifting treatment for GBM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
O’Connor, A. E., Gallagher, W. M., & Byrne, A. T. (2009) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2009.00585.x · Cited by 1,191
Cheng, Y., Cheng, H., Jiang, C., Qiu, X., Wang, K., Huan, W., Yuan, A., Wu, J., & Hu, Y. (2015) · Nature Communications · doi:10.1038/ncomms9785 · Cited by 941 · cited 1×
“Direct vessel injury has also been reported [31].”
BackgroundLight Sources and Dosimetry Techniques for Photodynamic Therapy
Kim, M. M., & Darafsheh, A. (2020) · Photochemistry and Photobiology · doi:10.1111/php.13219 · Cited by 454 · cited 1×
“Photoactivation of 5-ALA occurs at 635 nm, which can only penetrate 1–5 mm [25].”
BackgroundPhotodynamic therapy: illuminating the road from cell death towards anti-tumour immunity
Garg, A. D., Nowis, D., Golab, J., & Agostinis, P. (2010) · Apoptosis · doi:10.1007/s10495-010-0479-7 · Cited by 297 · cited 1×
“While there is preliminary evidence to suggest PDT has an immune-modulating effect on GBM TME, further research with reliable preclinical models is necessary [50,51].”
BackgroundAminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer
Wachowska, M., Muchowicz, A., Firczuk, M., Gabrysiak, M., Winiarska, M., Wańczyk, M., Bojarczuk, K., & Golab, J. (2011) · Molecules · doi:10.3390/molecules16054140 · Cited by 265 · cited 3×
“While not intrinsically fluorescent, 5-ALA is enzymatically converted to PpIX, a photosensitizer that can also be endogenously produced, by the heme biosynthesis pathway [12,13].”
BackgroundYang, X., Palasuberniam, P., Kraus, D., & Chen, B. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161025865 · Cited by 158 · cited 2×
“While not intrinsically fluorescent, 5-ALA is enzymatically converted to PpIX, a photosensitizer that can also be endogenously produced, by the heme biosynthesis pathway [12,13].”
BackgroundThe Hydroxypyridinone Iron Chelator CP94 Can Enhance PpIX‐induced PDT of Cultured Human Glioma Cells
Blake, E., & Curnow, A. (2010) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2010.00770.x · Cited by 51
ABCG2 influence on the efficiency of photodynamic therapy in glioblastoma cells
Müller, P., Abdel Gaber, S. A., Zimmermann, W., Wittig, R., & Stepp, H. (2020) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/j.jphotobiol.2020.111963 · Cited by 49
Cited by
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms
Chang, C., Chavarro, V. S., Gerstl, J. V. E., Blitz, S. E., Spanehl, L., Dubinski, D., Valdes, P. A., Tran, L. N., Gupta, S., Esposito, L., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126733 · Cited by 45
Challenges and Promise for Glioblastoma Treatment through Extracellular Vesicle Inquiry
Liguori, G. L. (2024) · Cells · doi:10.3390/cells13040336 · Cited by 24
“Photodynamic therapy (PDT) induces cell death in the target tissue through the production and accumulation of reactive oxygen species by a combination of light energy, oxygen, and photosensitizing cytotoxic agents [29,34,35].”
BackgroundInfluential
Metadata
- Authors
- Bhanja, D., Wilding, H., Baroz, A., Trifoi, M., Shenoy, G., Slagle-Webb, B., Hayes, D., Soudagar, Y., Connor, J., & Mansouri, A.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2023-06-30
- Volume
- 15
- Issue
- 13
- Pages
- 3427
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W4382982530
- Cited by
- 59
- References
- 8
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.